Feebris raises £1.1 million Seed funding for AI-powered disease diagnosis through 24 Haymarket and Innovate UK

  • The London-based healthtech startup has successfully secured £1.1 million seed funding, in collaboration with investment network 24 Haymarket and Innovate UK
  • Feebris is currently running a pilot with community healthcare workers in India to bring precision diagnosis for respiratory diseases to 10,000 children
  • The startup will also be working with 1,000 elderly patients in the UK to develop AI-powered remote monitoring for COPD and asthma

Founded by Elina Naydenova and Adam Bacon in 2017, and supported by healthtech accelerator HS.Google for StartupsSocial Tech Trust, and White & Case, Feebirs has just raised £1.1 million in seed funding, led by 24 Haymarket and including a grant from Innovate UK.

Feebris is an AI company developing world-class machine learning algorithms for precision detection of complex respiratory conditions in the field. Their software platform pairs with existing medical sensors and can be used intuitively by those with little or no medical training, even outside a clinic environment, to detect respiratory issues.

CEO Dr. Elina Naydenova holds a PhD in Machine Learning for Healthcare Innovation from Oxford University and created the concept for Feebris whilst interning at the World Health Organisation in 2014. “I was shocked that despite being a treatable condition, pneumonia kills one million children under-five every year – more than HIV, malaria, and TB combined. When I realised these deaths can be avoided through early diagnosis, I became obsessed with finding a way to solve the problem.”

Motivated by this, Elina has been working on this technology ever since and was also awarded $100,000 dollars in 2018 by the Children’s Prize Foundation, to scale the work in India.

“By putting our technology into the hands of frontline nurses and care workers, we will power the future of remote precision diagnosis, enabling patients to receive care before they are seriously ill, which means that clinicians are able to focus on patients rather than data. We aim to become a world-leader in the development of CE certified AI for respiratory disease diagnosis and monitoring.

This investment will support Feebris’ AI-enabled platform to continue bridging the gap between the community and providers across a range of respiratory conditions including pneumonia, COPD and asthma.”

Commenting on the investment, Paul Tselentis, CEO of 24Haymarket, said: “Feebris’s cutting-edge AI-platform has the potential to solve one of the most pressing problems in our healthcare systems and provide immense value to patients and physicians alike. This is an exciting time for Feebris; and 24Haymarket are pleased to be supporting them as they build on their early engagement with healthcare providers.”

Feebris supporters also reacted to the investment:

Dr James Somauroo Founding Partner of healthtech accelerator HS. said: “Feebris is a great example of how deep technology has been applied to a problem in healthcare by a very talented founding team with an innovative business model and we’re immensely proud to have been a part of their journey so far. This investment will enable the team to make an impact on a global scale and be a part of fundamentally changing the way that healthcare is delivered around the world, for the better.”

Marta Krupinska, Head of Google for Startups UK said “Feebris is an excellent example of a values-led company that uses technology to solve important social problems, and we’re thrilled that this is recognised by the ecosystem and the investors. We’re really excited to work with Feebris and support them on this next step in their journey”

Ed Evans, CEO of Social Tech Trust said, “We’re thrilled to see Feebris secure seed stage investment to support their growth.  Feebris share our vision for transforming the healthcare system and we see huge potential in their innovative approach.  Driven by passionate founders, I’m confident that Feebris will go on to create incredible social impact.”

About 24 Haymarket: 24Haymarket is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to £5 million in any company. 24Haymarket’s Investor Network includes several highly experienced private equity and venture capital investors, seasoned entrepreneurs and senior operators. These individuals invest their own capital in direct alignment with entrepreneurs and typically seek Board representation to actively support the growth agenda. Since its inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

About HS.: Founded by two doctors, HS. is an accelerator that builds, scales and invests in the best healthtech startups to tackle global health issues. They select talent at all stages and create a bespoke programme for each team – from individuals with ambitious ideas and excellent skillsets, to established companies looking to scale. HS. offers support to build internationally applicable technology from day one, to scale into multiple markets, including the NHS, private healthcare sector, insurance, B2C and emerging markets.

About Google for StartUps: Google for Startups is Google’s initiative to help startups thrive across every corner of the world. We bring the best of Google’s products, connections, and best practices to level the playing field for startup founders and communities, and enable startups to build something better.

About Social Tech Trust: Social Tech Trust’s purpose is to transform lives with tech and they’re dedicated to pursuing their vision of a world where social transformation is the driving force behind tech.  As a leading charity, in the last decade, the Trust has invested over £31 million and supported over 750 socially motivated tech ventures in the UK.

About White & Case: White & Case is a leading global law firm with lawyers in 44 offices across 30 countries. Among the first US-based law firms to establish a truly global presence, we provide counsel and representation in virtually every area of law that affects cross-border business. Our clients value both the breadth of our global network and the depth of our US, English and local law capabilities in each of our regions and rely on us for their complex cross-border transactions, as well as their representation in arbitration and litigation proceedings.

Tended secures £1.15 million of equity and grant funding in Seed Follow On from Blackfinch Ventures and Innovate UK

Minerva, a business angel network which is part of University of Warwick Science Park, has played a role in helping Lincoln-based tech start-up Tended access the funds and know-how needed to take its intelligent safety solutions to the next level.

Founded in August 2017, Tended creates intelligent wearables and safety solutions that can detect accidents and immediately notify the wearer’s emergency contacts with their GPS location, health and activity data.

After two Minerva pitching rounds, Tended secured a total of £935,000 through Minerva Business Angels, including a single investment of £810,000 from Blackfinch Ventures. They went on to secure a further £221,000 from Innovate UK, taking the total raised to £1.15m.

Liz McKenzie, Vice Chair of the West Midlands Growth Company and a Minerva Angel, took the lead in supporting the Tended investment across the Minerva network. She has joined the start-up as Chair to lend her expertise and contacts to the fledgling company.

The company’s founder, Leo Scott Smith, first approached Minerva in February 2018. He explained: “After seeing Tended pitch a couple of times at Minerva events, one of Blackfinch Ventures directors expressed an interest in investing. Initially, I thought it was just him acting as an individual Angel, so when I heard the investment was to be through Blackfinch and they were interested in investing £810k, it came as quite a shock! It also came at just the right time as we had a number of very exciting opportunities opening up, which required a much larger cash injection than previously anticipated.”

Alex Toft Head of Minerva, said: “We are absolutely delighted to have helped Tended secure such a significant investment, supporting their growth and creating new high-tech jobs in Lincolnshire.

“It’s a real testament to Minerva’s strategy of identifying great companies that are worthy of support, and linking them up with our Angels.

“Minerva Angels don’t just put their hands in their pockets. As Liz has done for Tended, our angels lend their credibility, vouching for these young companies across the Minerva network.

“It’s also great to see our own growth plans to improve access to Angel investment paying real dividends.”

Dr Reuben Wilcock, Ventures Director at Blackfinch, said “We were lucky to discover Tended at one of the Minerva Business Angel events and were impressed by the passion and drive of Leo and his team. Blackfinch is excited to be making this investment and keen to see Tended gain market traction with their intelligent wearables solution.”

Liz McKenzie, Minerva’s Lead Angel for the Tended raise, said: “Tended was one of my first investments as an Angel and to take the lead role was a great opportunity.

“Working together with my fellow Angel investors who can help support Tended demonstrates the important role we can play in the whole access to finance ecosystem for such companies.

“Being subsequently asked to become the Chair of Tended’s Board, was a great privilege and pleasure to accept, especially given my relevant background. My experience has been hard won, and it’s great when that experience can be used to support a young growing company. It’s also an additional benefit of Minerva, talented young companies can draw on a wealth of expertise.”

Leo Scott Smith, CEO of Tended added: “We are very excited to have received this investment to help develop safety solutions that could potentially save lives. It’s great to see Tended growing so quickly, made possible by the support of Minerva Business Angels.”

Source: https://www.eastmidlandsbusinesslink.co.uk/mag/finance/lincoln-tech-start-up-secures-1-15m/

Chief.AI secures £370k Grant funding from InnovateUK

‘Pay as you go’ Artificial Intelligence

Chief.AI and Medicines Discovery Catapult awarded funding to make AI accessible to all drug discovery researchers

Today [1 May 2019], Artificial Intelligence (AI) in drug discovery gains further support as Chief.AI and Medicines Discovery Catapult secure a grant from Innovate UK to make AI accessible to all drug discovery researchers.

This partnership will address the need for more accessible AI and data in the B2B marketplace – prioritising drug discovery, diagnostics and clinical trials markets.

By providing easy access to scarce but invaluable, cutting edge skills, resources and expertise, the platform will enable UK SMEs to leverage the power of AI at the click of a button, reinvigorating drug discovery by indirectly contributing to novel new drugs, treatments and diagnostics.

Users will be able to search by sector and/or keyword to discover and connect their own machine and database to the relevant AI algorithm on a pay as you go, on demand basis.

£370k funding will enable Chief.AI to create their searchable online platform, providing researchers with access to downloadable, off-the-shelf AI models, algorithms and high-quality data. Thus, connecting customers to suppliers in a secure, private environment, deriving revenue via commission and cloud provider charges.

Medicines Discovery Catapult will support the development of high-quality datasets and plan to provide exclusive access via the Chief.AI platform to their own novel AI algorithms; state-of-the-art image processing models capable of extracting information from pharmacological data and medical images in scientific journal papers to predict a potential drug targets performance.

The platform will be enriched through a comprehensive rating, benchmarking, pricing and scoring system and provide tailored sector relevant services as opposed to a one stop shop. Each AI algorithm will be further validated by customer use and experience.

New models for drug discovery are desperately needed. Around 90% of potential drug candidates fail and the cost of failure is enormous, ranging from $800m to $1.4bn[1]. For drugs targeting complex and poorly understood conditions, failure is near certain.

AI has the potential to solve many of the underlying issues with drug discovery. For example, deep learning algorithms could analyse molecules and predict how they might act in the human body at an earlier stage than in the traditional drug discovery process, potentially saving £billions in needless R&D and clinical trials

A number of companies are developing AI services and investment in AI for drug discovery is surging. However, lack of expertise and lack of knowledge about available services is a barrier to uptake. Furthermore, lack of sufficient high-quality structured and standardised data represents a major challenge in the implementation of AI.

Professor John Overington, Chief Informatics Officer of Medicines Discovery Catapult, says:

“This partnership and funding clearly indicate the importance and value of artificial intelligence as a new approach to support UK SMEs and reinvigorate drug discovery. Our aim is to help deliver a platform which is of high value to UK SMEs to advance their own drug discovery projects faster and more efficiently by accessing otherwise inaccessible, complex technical expertise”

Waqar Ali, Founder of Chief.AI says:

“The UK is where the first industrial revolution began, and we now want to accelerate AI provision throughout the world to become one of the biggest industrial force

multipliers of the twenty first century. Chief.AI will make the discovery of drugs more efficient, at lower cost and will diagnose diseases earlier to enable better outcomes.”

Dr Kath Mackay, Director – Ageing Society, Health & Nutrition, Innovate UK says:

“Harnessing the capabilities of AI in medicine and in other fields is a key component of the government’s modern industrial strategy. Innovate UK’s support for Chief.AI and Medicines Discovery Catapult will help to allow SMEs to work more efficiently and rapidly in the realm of drug discovery. This will lead to real benefits for patients and help expand and grow this vital sector.”

The capabilities of AI are predicted to drive Global GDP upwards of 14% by 2030[2], resulting in a total gain of $15.7 trillion2due to productivity and personalisation improvements. In the UK, the gain is predicted to be as large as 5% of GDP[3], and extra spending power per household of up to £1,800-£2,300 a year by 20303.

[1] https://www.clinicalleader.com/doc/the-high-price-of-failed-clinical-trials-time-to-rethink-the-model-0001

[2] https://press.pwc.com/News-releases/ai-to-drive-gdp-gains-of–15.7-trillion-with-productivity–personalisation-improvements/s/3cc702e4-9cac-4a17-85b9-71769fba82a6

[3] https://www.pwc.co.uk/economic-services/assets/ai-uk-report-v2.pdf

Source: https://bionow.co.uk/news/b5cc95bb62cd40/chief-ai-and-medicines-discovery-catapult-awarded-funding-to-make-ai-accessible-to-all-drug-discovery-researchers

OpusVL led consortium secures £790k Grant funding from Innovate UK.

Leading UK Open Source software integrator, OpusVL, today announced that its consortium has been awarded a £790,000 government grant to develop re-usable Open Source applications for the UK healthcare sector. The sum is the largest Innovate UK research and development grant awarded to an Open Source project1.

The grant is for the development of processes for creating and delivering Open Source software to the UK healthcare sector as part of a wider open approach, aligned with the mandate of the new NHSx2 government department. The project includes proof of concept through the creation and validation of an app that calculates the National Early Warning Score, a key predictor of sepsis in hospital patients, which claims the lives of an estimated 46,000 people a year3 in the UK.

The 19-month project will research and implement a new digital electronic observation (eObs) solution to identify deteriorating patients. Notably, not only does the solution connect through open standards to other hospital systems, the software, design, documentation and all associated components will be made available to the community to be studied, re-used and further developed.

Its ultimate aim is to create a blueprint for clinician-led open software design that delivers the exact functionality – with future flexibility and integrated in to the NHS networks – needed to optimise NHS patient care, while reducing the NHS’s £7bn annual software licence renewal bill.

The ground-breaking practical study will work with doctors and nurses to evaluate current NHS working practices, identifying strengths and weaknesses. A best practice approach will then be implemented in the app, before being tested in a cutting-edge hospital simulator. The last stage of the project will be field trials at hospitals in two NHS Trusts, before the final report is delivered.

OpusVL is the lead partner in the consortium, joined by the South London and Maudsley NHS Foundation Trust, Cheshire and Wirral Partnership NHS Foundation Trust, The Apperta Foundation CIC Trust, Open UK and a leading UK University. The combination of academic rigour, clinical partnership and technological expertise harnessed by the consortium for this study heralds a turning point in the NHS’s approach to open source software.

Stuart J Mackintosh, CEO of OpusVL said, “We’re thrilled to have been given the opportunity by Innovate UK to prove that professional open source is the only viable solution to the NHS’s complex software needs. Innovate UK understood that we have ambitious aims to transform the NHS’s approach to digital technology, helping to create software that is the perfect clinical fit for today and adaptable for tomorrow saving lives and money simultaneously.”

The project launches on 1st April , with trials due to start in May 2020. Project progress will be presented at key UK healthcare events with final research findings published in August next year.

For more information please contact: Lauren Westley, OpusVL, 01788 298456

NOTES

  • OpusVL is the UK’s most established Open Source software integrator, solving business problems with world-class Open Source digital technology solutions.
  • Celebrating 20 years in business in 2019, OpusVL was founded by Stuart J Mackintosh and now employs over 25 talented staff at its headquarters in Rugby, Warwickshire.
  • OpusVL helps customer meet their goals by developing and supporting perfectly tailored, flexible open software, free of costly licence renewal fees. Its customers are organisations in the private and public sectors whose needs are not being met by ‘off the shelf’ solutions and those who wish to break free of the limitations and high costs of proprietary software. For further information, please visit https://opusvl.com
  • The Apperta Foundation CIC Trust is a clinician-led, not-for-profit company. Supported by NHS England, NHS Digital and others, it promotes open systems and standards for digital health and social care. Apperta shows how the delivery of health and social care can be
  • transformed when data, information and knowledge in IT systems is open, shareable and
  • computable. For more information, visit https://apperta.org/
  • South London and Maudsley NHS Foundation Trust provides the widest range of NHS mental health services in the UK. For further information, visit https://www.slam.nhs.uk/
  • Cheshire and Wirral Partnership NHS Foundation Trust provides mental health, learning
  • disability and community physical health services. For further information, visit http://www.cwp.nhs.uk
  • OpenUK is the UK open source industry association representing the open source business
  • community across the UK and focused on stimulating the professional UK supply chain. For further information, visit https://openuk.uk

HealthTech company Cog-Neuro Speech Therapy secures £85k Grant and Debt finance from InnovateUK and Development Bank of Wales

People suffering with communication difficulties are benefitting from a new speech therapy service that has been developed by Caerphilly-based Cog-Neuro Speech Therapy Limited.

With a £25,000 loan from the Development Bank of Wales and a £60,000 grant from Innovate UK, the mobile application has been developed to help people with communication difficulties to regain their ability to communicate, maintain relationships and re-integrate into the community. 

Cog-Neuro was first established by speech therapist Sheiladen Montero Aquino in 2012. She has now developed an application that will enhance speech therapy service for people with communication difficulties following a stroke, brain injury, and other progressive neurological disorders including Parkinson’s disease and Multiple Sclerosis.

By using the application, patients can access services during the time when they are most stimulable for rehabilitation or while waiting for a speech therapy appointment from the NHS. Patients and their families who want intensive speech therapy can also use the app alongside speech therapy sessions to support their current rehabilitation program.

The Cog-Neuro application focuses on five areas of language including listening, speaking, reading, writing and thinking (semantics). Gamification and stealth learning has been used to encourage interactivity and concentrated attention, which have been shown to be key factors in neuroplasticity and brain regeneration.

Mini-games target specific linguistic skills with visual instructions and trial options at the start of each game. Feedback is given to users. In addition, each of the games has three levels of difficulty depending on the user’s  progress. At the end of the game a report is generated which can be sent via email. It is also possible to customise the game for the client.

Sheiladen Montero Aquino founder of Cog Neuro said: “Throughout my international practice in speech therapy, I have wanted to develop an innovative treatment that will help people communicate again after a stroke, brain injury, Parkinson’s or Dementia.

“The Innovate UK funding helped develop the mobile software but we still needed additional finance. Business Wales introduced me to Rhiannon Brewer at the development bank – she understood our business and showed a sincere desire for our success.  She guided me through the process and we received the funds promptly. We found a reliable partner for this journey!

“I’m grateful to the Development Bank of Wales, Business Wales and Innovate UK for their excellent support throughout.”

Rhiannon Brewer, Senior Investment Executive with the Development Bank of Wales said: “Working in partnership with other funders and business support organisations to help ambitious and passionate business owners to succeed is what we do best. Each company we work with is different and every deal is bespoke. So, I was particularly pleased  to work with Business Wales and Innovate UK to offer a funding package that really is making a difference to the business whilst improving people’s lives.

“The new product from Cog-Neuro will help to benefit some of the 15,500 people in Wales who are estimated to suffer with severe speech and communication problems. It’s very rewarding to know that our micro loan is now helping to ensure that people will receive the care  they need to support independence and quality of life.”

David apjohn-Williams, Business Wales Regional Manager for South Wales, said: “As well as supporting entrepreneurs and SMEs across Wales to start and expand, collaborating with other support organisations and stakeholders to offer a holistic approach that is tailored to the individual, is paramount to us.

“I am delighted that, together with the Development Bank of Wales and Innovate UK, our advisers were able to support Sheiladen and Cog Neuro to create a robust financial plan and secure the micro loan, as the business continues to develop their life-changing projects.”

The Development Bank of Wales offers micro-loans from £1,000 to £50,000 as well as loans and equity up to £5 million.

UK AI companies Biorelate and Intellegens win share of £20m in Innovate UK grant competition to explore creation of advanced data curation tool

2019-02-18. Manchester, UK and Cambridge, UK. Two artificial intelligence (AI) companies, Biorelate Limited and Intellegens Limited, today announced their success in the third round of the Innovate UK open grant funding competition. Together, the two companies have secured over £300,000 from Innovate UK and will co-invest an additional £130,000 to deliver a partnership project entitled: “Chemeia: A synergistic AI integrated architecture for augmenting high-value dark-data”.

Project Chemeia (‘Chem-ee-a’) will test the potential for combining the capabilities of Biorelate’s deep text mining (Galactic AITM) technology with Intellegens’ sparse data solution, to produce up to date, comprehensive, and reliable data sets for high-value R&D work.

Biorelate and Intellegens are two high-technology companies specialising in the development and application of novel AI techniques that can solve common problems associated with optimising data curation for R&D.

Data curation is a critical component of scientific research and development (R&D) in many areas including biological research and advanced materials manufacturing – helping to ensure that results from in-house experiments and information from external sources can be integrated for further analysis.

Current AI methods for curating scientific experimental data can be slow and are prone to leaving gaps in the information they produce. Existing techniques are costly to deploy at scale. Estimates suggest that around 80% of published scientific literature is unused and the effort of data curation is an obstacle to research. This project will determine how modern AI approaches can make this better.

Biorelate CEO and founder Dr Daniel Jamieson said ‘Adequate data curation underpins so much of the future success of research and development in science and Biorelate is continually investing in innovative ways to improve this. What really excites me about this project is the prospect of bringing two completely different, game-changing technologies together to achieve something entirely novel. We can’t wait to start!’

Intellegens CEO and co-founder Ben Pellegrini said ‘We are excited to work with the team at Biorelate to bring together the best parts of our AlchemiteTM platform with Galactic AITM. Independently, our AI technologies are proven; together they have the potential to take the pain out of data curation. Biorelate curates databases from the analysis of published scientific literature – allowing researchers to extract structured biological knowledge for use in a variety of applications. We work with sparse data, using our deep learning algorithm to make accurate predictions in datasets that are as little as 0.05% complete. With the funding granted by Innovate UK we’ll be able to exploit the synergies between these two approaches and see if it is possible to create a powerful new approach that can transform data curation.”

Both CEOs agreed that ‘Funding from Innovate UK has made this project possible. This support will help us contribute to the UK’s position as a leading nation in this field.’

Biorelate, Manchester Science Park, Manchester, UK, M15 6JJ

Biorelate is developing Galactic AITM, an advanced text analytics & data mining cloud-based platform. Galactic reduces research risks, increases commercial awareness and helps solve biomedical research’s greatest challenges.

https://www.biorelate.com

Intellegens, Eagle Labs, 28 Chesterton Road, Cambridge, Cambridgeshire, United Kingdom, CB4 3AZ

Intellegens have developed Alchemite, which builds on existing numerical curated resources (sparse data) by using AI to predict ranked unknown data-points and uncertainties. No other solution on the market can replicate Alchemite’s low cost modelling, prediction, error detection & parameter optimisation for big, sparse, numerical data.

https://www.intellegens.co.uk

Innovate UK, the UK’s innovation agency

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation.

https://www.innovateuk.ukri.org

Mendelian receives over £500,000 from InnovateUK to help identify patients with rare or hard to diagnose conditions

Mendelian, a UK healthtech startup, has received a grant from Innovate UK to build solutions that will assist GPs in identifying NHS patients who potentially have rare or hard to diagnose conditions and diseases. The grant is being used to implement the company’s specialised screening system, which provides augmented intelligence and data analysis to deliver the fast, accurate and automated identification of patients who may fit the rare disease or difficult to diagnose categories. Once the technology has analysed a patient’s symptoms, they are then flagged to the GP who has various options, including referring the patient to a specialist or recommending further analysis and testing.

Research has shown that in the UK it takes an average of 5.6 years, eight clinicians (including four specialists) and three misdiagnoses before the correct rare disease is identified*. A further health economics report commissioned and released in November last year by Mendelian revealed that over the last 10 years, rare disease patients while undiagnosed have cost the NHS in excess of over £3.4 billion.

Dr. Peter Fish, Head of Clinical Partnerships at Mendelian said: “It’s clear that this ‘diagnostic odyssey’ is not only causing patients distress and emotional turmoil but is also extremely frustrating for clinicians, as well as costly for healthcare systems and ultimately tax-payers. To help solve this pressing issue we’re delighted to be providing a solution within the NHS, for not only rare disease patients, but also those with hard to diagnose conditions. Crucially, Mendelian’s technology is being implemented at the general practice stage, right at the beginning of the patient journey with the aim of identifying these conditions as early on as possible.”

Piers Ricketts, Chief Executive at the Eastern Academic Health Science Network, said:

“We are delighted to support Mendelian as part of our work into rare diseases. With over 3 million rare disease patients in the UK, innovative technologies using data analytics and machine learning like this are increasingly vital in ensuring that these conditions are diagnosed earlier to provide more targeted and personalised treatment for patients.”

The total budget for the project is £940,000 with over £500,000 of this awarded to Mendelian by Innovate UK – a non-departmental public body and the UK’s innovation agency – in order to develop and implement the technology. The project is set to run over the next two years with the first trial currently taking place in Hertfordshire, in partnership with the Eastern Academic Health Science Network (EAHSN) and NHS East and North Hertfordshire Clinical Commissioning Group (CCG).** Following this, the technology will potentially be rolled out to further areas in the UK, as well as globally in the near future.

*https://globalgenes.org/wp-content/uploads/2013/04/ShireReport-1.pdf

** The trial will analyse pseudonymised electronic medical records to find patients that should be investigated further for rare or hard to diagnose diseases and the protection of patient data will be prioritised at all times throughout.

About Mendelian

Mendelian is a technology company building the world’s largest repository of information to help accelerate the diagnosis of rare diseases. The company is a team of eight based in London, with a wealth of experience across a range of complimentary disciplines including business, machine learning, data science, design and medicine. Currently Mendelian’s free service has been used by clinicians and specialists (geneticists, pediatricians, neurologists, cardiologists) across a range of disciplines in more than 150 countries.  ­­­
For further information, interviews and images, please contact: mendelian@33seconds.co